---
id: entamoeba-malaria_337
category: organisms
tags: [Entamoeba-histolytica, amebiasis, liver-abscess, malaria, Plasmodium, artemisinin, ACT, resistance]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Entamoeba histolytica & Malaria (Plasmodium Species)

**Q:** What are the treatments for amebiasis, amebic liver abscess, and malaria (including artemisinin resistance)?

**A:**

**Entamoeba histolytica (Amebiasis):**

| Disease Form | Treatment | Duration | Notes |
|--------------|-----------|----------|-------|
| **Asymptomatic intestinal** | **Paromomycin 500 mg PO TID** OR iodoquinol | **7 days** | Treat to prevent disease (4-10% develop symptoms within 1 year) + prevent transmission |
| **Symptomatic intestinal/dysentery** | **1. Metronidazole 750 mg PO TID** OR tinidazole<br>**2. THEN paromomycin 500 mg PO TID** | **7-10 days**<br>**7 days** | Sequential therapy; **do NOT give simultaneously** (diarrhea from paromomycin confounds assessment) |
| **Amebic liver abscess** | **1. Metronidazole 750 mg PO TID**<br>**2. THEN paromomycin 500 mg PO TID** | **7-10 days**<br>**7 days** | Metronidazole kills trophozoites; paromomycin eradicates luminal cysts (40-60% persist after metronidazole alone) |

**Key Points:**
- **Metronidazole**: Kills trophozoites in tissue but does NOT eradicate cysts
- **Paromomycin**: Aminoglycoside; poorly absorbed; kills luminal forms only
- Sequential therapy required for invasive disease to prevent relapse

---

**Malaria (Plasmodium Species):**

| Species | Disease Pattern | First-Line Treatment (WHO 2024) |
|---------|----------------|--------------------------------|
| ***P. falciparum*** | Severe/cerebral malaria | **Artesunate IV** 2.4 mg/kg at 0, 12, 24h, then daily × 3 days minimum |
| ***P. falciparum*** (uncomplicated) | Chloroquine-resistant (most areas) | **Artemisinin-based combination therapy (ACT)**:<br>- Artemether-lumefantrine (AL)<br>- Artesunate-amodiaquine (AS+AQ)<br>- Dihydroartemisinin-piperaquine (DHAP) |
| ***P. vivax, P. ovale*** | Relapsing (hypnozoites in liver) | **ACT + primaquine** (14 days) to prevent relapses<br>(Check G6PD status first) |
| ***P. malariae*** | Chronic low-grade | ACT or chloroquine (if sensitive) |
| ***P. knowlesi*** | Zoonotic (Southeast Asia) | ACT |

**WHO 2024 Updates:**
- **New ACT**: Artesunate-pyronaridine (ASPY)
- **First trimester pregnancy**: Revised recommendations now allow ACTs
- **Weight-based dosing**: Optimized dihydroartemisinin-piperaquine for young children

**Artemisinin Resistance:**
- **Definition**: Delayed parasite clearance (>3 days); PfKelch13 mutations
- **Geography**: Greater Mekong Subregion (GMS); **now reported in Rwanda** (2024)
- **Clinical impact**: Nearly all patients still cured IF partner drug remains efficacious
- **Concern**: Resistance to partner drugs (piperaquine, mefloquine) causing ACT failures in Southeast Asia

**Key Points:**
- **Artesunate IV** for severe malaria (superior to quinine)
- **ACTs** are standard for uncomplicated *P. falciparum*
- **Primaquine** required for *P. vivax/ovale* to eradicate hypnozoites (check G6PD)
- **Artemisinin resistance spreading**: Requires genomic surveillance, frequent efficacy testing

**Mnemonic - "Ameba = Metronidazole THEN Paromomycin (sequential), Malaria = ACT (combination)"**

**Pearl:** Amebiasis requires sequential therapy: metronidazole (tissue) → paromomycin (luminal cysts). Never give simultaneously (paromomycin diarrhea confounds assessment). Malaria treatment: artesunate IV for severe disease; ACTs for uncomplicated. Artemisinin resistance now in Africa (Rwanda 2024).

**Media:**

**Sources:** [CDC Yellow Book 2024 Amebiasis], [WHO Malaria Treatment Guidelines Nov 2024], [PMC11757681 - WHO Malaria Updates 2025], [Lancet ID - Artemisinin Resistance Africa 2024]
